Furthermore, the use of beta‐blockers was linked to reduced cancer‐specific mortality, thereby supporting the therapeutic potential of β2AR antagonists for EBV+ DLBCL. This evidence concerns the gene ADRB2 and diffuse large B-cell lymphoma.